Alison Quinn's Respiro Diagnostics raises GBP 1M for breath-based lung diagnostics

The UK company plans a September 2026 lung cancer clinical study after early proof-of-concept work in mesothelioma patients.

By · Published

Illustration of Respiro Diagnostics' breath analysis device connected to a schematic of human lungs.

The UK company plans a September 2026 lung cancer clinical study after early proof-of-concept work in mesothelioma patients.